Physical Exercise for Treatment of Depression and Anxiety - RCT
NCT04714528, Not applicable, Active not recruiting, Region Örebro County
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Physical Exercise for Treatment of Depression and Anxiety - RCT | ClinicalTrials.gov |
| NCT number | NCT04714528 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 87 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Region Örebro County | ClinicalTrials.gov |
| Conditions | Depression, Anxiety | ClinicalTrials.gov |
| Interventions | Physical Exercise, Relaxation Therapy | ClinicalTrials.gov |
| First posted | 2021-01-19 | ClinicalTrials.gov |
| Last updated | 2024-05-02 | ClinicalTrials.gov |
Registered outcomes 24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Symptom improvement in depression | Change of the score from the baseline to the score at 12 weeks. | Improvement of symptom severity grade are assessed with Montgomery-Åsberg Depression Rating Scale (MADRS). The minimum and the maximum score is 0 and 60 respectively, and the higher score means a worse outcome. | ClinicalTrials.gov |
| Primary | Symptom improvement in depression | Change of the score from the baseline to the score at 1 year. | Improvement of symptom severity grade are assessed with Montgomery-Åsberg Depression Rating Scale (MADRS). The minimum and the maximum score is 0 and 60 respectively, and the higher score means a worse outcome. | ClinicalTrials.gov |
| Primary | Symptom improvement in anxiety | Change of the score from the baseline to the score at 12 weeks. | Improvement of symptom severity grade are assessed with Beck Anxiety Inventory (BAI). The minimum and the maximum score is 0 and 63 respectively, and the higher score means a worse outcome. | ClinicalTrials.gov |
| Primary | Symptom improvement in anxiety | Change of the score from the baseline to the score at 1 year. | Improvement of symptom severity grade are assessed with Beck Anxiety Inventory (BAI). The minimum and the maximum score is 0 and 63 respectively, and the higher score means a worse outcome. | ClinicalTrials.gov |
| Primary | Subjective symptom improvement in depression | Change of the score from the baseline to the score at 12 weeks. | Improvement of symptom severity grade are assessed with Montgomery-Åsberg Depression Rating Scale Self-Rating Version (MADRS-S). The minimum and the maximum score is 0 and 60 respectively, and the higher score means a worse outcome. | ClinicalTrials.gov |
| Primary | Subjective symptom improvement in depression | Change of the score from the baseline to the score at 1 year. | Improvement of symptom severity grade are assessed with Montgomery-Åsberg Depression Rating Scale Self-Rating Version (MADRS-S). The minimum and the maximum score is 0 and 60 respectively, and the higher score means a worse outcome. | ClinicalTrials.gov |
| Secondary | Cognitive function: Trail Making Test Part A&B | Comparison of results between baseline and week 12. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Trail Making Test Part A&B | Comparison of results between baseline and year 1. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Symbol Digit Modalities Test | Comparison of results between baseline and week 12. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Symbol Digit Modalities Test | Comparison of results between baseline and year 1. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Corsi Block-Tapping Test forward | Comparison of results between baseline and week 12. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Corsi Block-Tapping Test forward | Comparison of results between baseline and year 1. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Rey Auditory Verbal Learning Test | Comparison of results between baseline and week 12. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Rey Auditory Verbal Learning Test | Comparison of results between baseline and year 1. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Stroop test | Comparison of results between baseline and week 12. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Cognitive function: Stroop test | Comparison of results between baseline and year 1. | Cognitive functions are measured using digitized cognitive tests selected for depression in cooperation with Mindmore. | ClinicalTrials.gov |
| Secondary | Clinical Global Impression (CGI) severity scale | Up to 1 year from baseline. | Clinician's impression of total severity of the mental illness. Scale between 0 and 7, higher point indicates worse outcome. | ClinicalTrials.gov |
| Secondary | Posttraumatic Stress Disorder Checklist (PCL-5) | Up to 1 year from baseline. | Measures symptoms in posttraumatic stress disorder. Total points 0-80, higher point indicates worse outcome. | ClinicalTrials.gov |
| Secondary | Adult ADHD Self-Report Scale (ASRS) | Up to 1 year from baseline. | Measures symptoms in attention deficiency and hyperactivity disorder (ADHD). Minimum 0 point to maximum 72 points. Higher point indicates worse outcome. | ClinicalTrials.gov |
| Secondary | Perceived Stress Scale (PSS-14) | Up to 1 year from baseline. | Measures perceived stress. Minimum 0 point to maximum 56 points. Higher point indicates worse outcome. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 31681117 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Corsi Block-Tapping Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)